



INTERNATIONAL
ASSOCIATION OF
THERAPEUTIC DRUG
MONITORING AND
CLINICAL TOXICOLOGY



June 2020 | IATDMCT Monthly E-News



FEATURED IN THIS ISSUE:

- »» Letter from the President
- »» Update on 2020 Congress – We've Gone Virtual!
- »» Looking Forward to the 2021 Rome Congress
- »» 2020 IATDMCT Membership Renewal Reminder
- »» News from the Communication Committee
- »» Published Ahead-of-Print in *Therapeutic Drug Monitoring* – Latest Update
- »» Contact E-News

Letter from the President

Dear members,

I hope that you are continuing to stay safe and healthy during this difficult time. We have all had extremely unusual experiences and sudden changes in our daily life and working/studying circumstances due to the COVID-19 pandemic. At the same time, I sincerely thank all medical and laboratory professionals for their devoted efforts to fight the virus and care patients.

Even in this challenging situation, I am pleased to see our IATDMCT colleagues demonstrate their expertise to contribute to medical service and public health. For example, the Immunosuppressive Drugs Committee has published a timely article in our TDM journal to alert clinicians on potential drug interactions with experimental COVID-19 treatments in transplant recipients. As discipline of TDM and CT, every member can do something, even small thing to support people. Please use your knowledge, skills and accumulated experiences.

While it will be some time until the world returns to a more normal status, IATDMCT continues to support members. Although the Banff Congress this September was forced to cancel sadly due to the COVID-19 pandemic, I look forward to near future when we can meet together discussing science and exchanging activities.

"There is always light behind the clouds." (*Louisa May Alcott*)

Yusuke Tanigawara
IATDMCT President

IATDMCT members acknowledge the effort made by the local organizers of the Banff meeting: David W. Kinniburgh, Penny Colbourne as well as Pamela Lyons and Megan Howes (office) for their dedicated work.

We are looking forward to the next year meeting in Rome, Italy.

[Top](#)

Update on 2020 Congress – We've Gone Virtual!

Save the Dates – September 14-16 2020

We are pleased to announce that in lieu of the in-person Congress event that was planned to be held in Banff, Canada, we are planning to present a virtual Congress on September 14-16. This event will entail 3 days of 3-4 hours per day of online presentations, and a virtual poster hall.

The event will be presented in real time to registered participants, and sessions will also be recorded and posted on the IATDMCT website in a restricted access section.

The Organizing Committee is currently working with IATDMCT Council to develop the virtual program and launch the registration. Watch your email for more details coming soon!

Stay tuned to IATDMCT for program updates... | [Top](#)

Looking Forward to the 2021 Rome Congress

We are looking forward to the next year meeting in Rome, Italy.

We would like to show you what to expect next September! » [Click here for Zefirelli's Rome](#)

» [Click here to view the Rome Congress brochure.](#)

Stay up to date on Rome 2021 – Congress Website... | [Top](#)

2020 IATDMCT Membership Renewal Reminder

Join us in maintaining the IATDMCT membership at a high level!. We look forward to inspiring many further colleagues who are interested in precision medicine to connect with us and to be part of IATDMCT. Our aims are to advance education, advocate networking, and to continue promoting a standard of practice in TDM and CT.

Please ensure you renew your membership in order to retain your IATDMCT member benefits.

» [Click here to renew today](#)

Renew today... | [Top](#)

News from the Communication Committee

Take advantage of networking in IATDMCT!

In these challenging times, IATDMCT continues to support laboratory medical and technical professionals, toxicologists, pharmacologists as well as our colleagues in biotechnology and supplier companies.

Some of our members are currently conducting clinical tests for COVID-19 and/or trying to introduce new biomarkers to monitor recovery. Certainly it is our duty to continue also the routine work. Keep safe.

Below please find informative links about the current situation which specifically address the rapid identification of COVID-19 cases as well as methods to eliminate errors or adverse reactions due to interaction of drugs:

- IATDMCT website provides a list of COVID-19 resources
 - <https://iatdmct.org/rss/7-news/556-covid-19-resources.html>
- Drugs used to treat COVID-19 that may interact with other medication
 - [Liverpool COVID-19 Interactions](#)
- Centre for Disease Control via NIH and Biosafety
 - <https://www.nih.gov/coronavirus>
 - <https://www.cdc.gov/coronavirus/2019-ncov/lab/biosafety-faqs.html>
- ASPX-drug compatibility
 - <https://www.interactivehandbook.com/Compatibility.aspx>
- New England Journal of Medicine opened all articles regarding Covid-19
 - <https://t.co/fkKzCwma7t>
- McMaster University
 - <https://www.mcmasterforum.org/find-evidence/guide-to-covid-19-evidence-sources>
- Cochrane
 - <https://covidrapidreviews.cochrane.org/welcome>

Visit the COVID-19 resources on the IATDMCT Website... | [Top](#)

Published Ahead-Of-Print in *Therapeutic Drug Monitoring* – Latest Update

Stay ahead with the latest scientific research developments in the fields of TDM and CT!

The monthly *Therapeutic Drug Monitoring* Column provides you with the latest posts of ahead-of-print. Bringing to you articles posted online in May 29 2020:

Review Articles:

- Usage of Tacrolimus and Mycophenolic Acid During Conception, Pregnancy, and Lactation, and its Implications for Therapeutic Drug Monitoring: A Systematic Critical Review.

By Le, Hoang Lan; Francke, Marith; Andrews, Louise M.; de Winter, Brenda C.M.; van Gelder, Teun; Hesselink, Dennis A.



Original Articles:

- Therapeutic monitoring of lacosamide in Japanese patients with epilepsy—Clinical response, tolerability, and optimal therapeutic range.
By Yamamoto, Yoshiaki; Terada, Kiyohito; Araki, Yasukiyo; Fukushima, Yutaro; Imai, Katsumi; Kagawa, Yoshiyuki; Takahashi, Yukitoshi
- Phenotyping of uracil and 5-fluorouracil metabolism using LC-MS/MS for prevention of toxicity and dose adjustment of fluoropyrimidines.
By Tafzi, N; Woillard, JB; Fleytoux, A; Picard, N; Marquet, P
- Evaluation of extrapolation methods to predict trough concentrations to guide therapeutic drug monitoring of oral anticancer drugs.
By Janssen, Dr. Julie M.; Dorlo, Thomas P.C.; Beijnen, Jos H.; Huitema, Alwin D.R.
- Evaluation of imatinib concentrations in samples submitted for BCR-ABL1 or imatinib testing – evidence to support therapeutic drug monitoring for dose optimization?
By Smy, Laura; Sadler, Aaron J.; McMillin, Gwendolyn A.
- High-Performance Liquid Chromatography for Therapeutic Drug Monitoring of Serum Lenvatinib.
By Watanabe, Yusuke; Doki, Kosuke; Sekine, Ikuo; Hara, Hisato; Homma, Masato
- No Apparent Influence of Non-Adherence on Tacrolimus Intra-Patient Variability in Stable Kidney Transplant Recipients.
By Gokoel, Sumit R.M.; Zwart, Tom C.; Moes, Dirk Jan A.R.; van der Boog, Paul J.M.; de Fijter, Johan W.
- Model-informed Bayesian Estimation Improves the Prediction of Morphine Exposure in Neonates and Infants.
By Euteneuer, Joshua C.; Mizuno, Tomoyuki; Fukuda, Tsuyoshi; Zhao, Junfang; Setchell, Kenneth D. R.; Muglia, Louis J.; Vinks, Alexander A.
- Perils of Antithrombotic Transitions: Effect of Oral Factor Xa Inhibitors on the Heparin Antifactor Xa Assay.
By Ahuja, Tania; Yang, Irene; Huynh, Quy; Papadopoulos, John; Green, David
- Chronopharmacokinetics and Food-Effects of Single-Dose LCP-tacrolimus in Healthy Volunteers.
By Alloway, Rita R.; Trofe-Clark, Jennifer; Brennan, Daniel C.; Kerr, Janice; Cohen, Elizabeth A.; Meier-Kriesche, Ulf; Stevens, Daniel R.; Moten, Misbah A.; Momper, Jeremiah D.
- Association Between Serum Carnitine Level and Ammonia and Valproic Acid Levels in Patients with Bipolar Disorder.
By Yokoyama, Saaya; Yasui-Furukori, Norio; Nakagami, Taku; Miyazaki, Kensuke; Ishioka, Masamichi; Tarakita, Natsumi; Kubo, Kazutoshi; Sugawara, Norio; Shimoda, Kazutaka

Short Communication:

- The Feasibility of Dried Blood Spots in Children with Behavioral Problems.
By Kloosterboer, Sanne M.; van Eijk, Estelle; van Dijk, Monique; Dieleman, Gwen C.; Hillegers, Manon H. J.; van Gelder, Teun; Koch, Birgit C.; Dierckx, Bram

Letters to the Editor:

- Measurement uncertainty in forensic toxicology.
By Malaca, Sara; Carlier, Jeremy; Pichini, Simona; Busardò, Francesco Paolo
- Important interactions of immunosuppressants with experimental therapies for novel coronavirus disease (COVID-19): how to act.
By Zijp, Tanja R.; Toren-Wielema, Martha L.; Nannan Panday, Prashant V.; Kosterink, Jos G.W.; Berger, Stefan P.; Touw, Daan J.

Submit your high quality research – Information for authors.

Visit the Therapeutic Drug Monitoring (TDM) Website to read your Articles of Interest... | [Top](#)

Contact E-News



Co-editor: Manuela Neuman

Co-editor: Ryuji Kato

NOTE: Items appearing in the IATDMCT monthly E-News do not necessarily have the endorsement of the Association.

Email your Hot Topic to IATDMCT Monthly E-News... | [Top](#)

IATDMCT | International Association of Therapeutic Drug Monitoring and Clinical Toxicology

info@iatdmct.org | www.iatdmct.org

4 Cataraqui Street, Suite 310 | Kingston, Ontario | K7K 1Z7 | CANADA

Tel: +1-613-531-8166 | Fax: +1-613-531-0626

[Unsubscribe](#)